CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.

Study Summary

Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.

Interventions

Study Locations

Facility	City	State	Country
Uppsala University Hospital, Dept of Oncology	Uppsala		Sweden

Official Trial Information

View on ClinicalTrials.gov